Acceptability of Hepatitis B Vaccination in General Practitioners and Paediatricians
NCT01777074 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 474
Last updated 2013-02-04
Summary
The present study is conducted in order to assess the acceptability of Hepatitis B vaccination in French general practitioners and peadiatricians before and after reimbursement of the paediatric vaccine InfanrixHexa. Two data measurement time points are planned, first before reimbursement and after reimbursement.
Conditions
Interventions
- OTHER
-
Data collection
Questionnaire, Vaccination book
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-11-30
- Primary Completion
- 2012-04-30
- Completion
- 2012-04-30
Countries
- France
Study Locations
More Related Trials
-
Hepatitis B Vaccination in Infants
NCT01896596 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates
NCT01183611 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)
NCT00414050 ·Status: COMPLETED ·Phase: PHASE3
-
Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)
NCT01463683 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
NCT00753649 ·Status: COMPLETED ·Phase: PHASE4
-
Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.
NCT02697474 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA
NCT02012998 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)
NCT00441012 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Vaccine Funding by the National Health Insurance on Vaccination Coverage Among Patients Targeted by Current Vaccination Recommendations and Followed in Outpatient Consultations
NCT07243236 ·Status: RECRUITING
-
Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b
NCT05401305 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine
NCT01353703 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects
NCT00323050 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age
NCT00345579 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants
NCT01226953 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age
NCT01470287 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age
NCT01019772 ·Status: COMPLETED ·Phase: PHASE3
-
Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth
NCT00317122 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV Vaccines
NCT00366366 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC
NCT00322335 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)
NCT02759354 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers
NCT04535037 ·Status: COMPLETED ·Phase: PHASE4
-
Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18
NCT06347627 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study
NCT01251133 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly
NCT01457495 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b
NCT00734565 ·Status: COMPLETED ·Phase: PHASE1